Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Kurve Therapeutics Announces Development of New Intellectual Property to Target Drug Delivery in the Brain
Today, Kurve Therapeutics announced it has filed for new intellectual property on its nose to […]
ReCode Therapeutics Announces First Participants Dosed in a Healthy Volunteer Clinical Trial for the Treatment of Primary Ciliary Dyskinesia
ReCode Therapeutics, a private, clinical-stage genetic medicines company using superior delivery to power the next […]
DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and macrophages […]
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, […]
Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder
Myosin Therapeutics, a biotechnology company leveraging its innovative platform technology to identify new molecular entities […]
Catamaran Bio Selects OmniaBio as Partner to Develop and Manufacture Allogeneic CAR-NK Cell Therapies
Catamaran Bio, a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio, […]
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Mirum Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has approved […]
InDex Pharmaceuticals Announces Positive Results from a Pharmacokinetic (PK) Study with Cobitolimod
InDex Pharmaceuticals has announced positive results from a pharmacokinetic (PK) study with cobitolimod in patients […]
WAKIX® (Pitolisant) Receives Approval for the Treatment of Narcolepsy in Children Over 6 Years of Age, a Rare, Under-Diagnosed Condition
The European Medicines Agency has just granted an extension of the indication for the marketing […]
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
Mediar Therapeutics, a biotechnology company advancing a portfolio of first-in-class therapies that halt and even […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more